Biology/Targets focuses on M. tuberculosis biology, the exchange of information to improve decision making for target selection and treatment strategies, and helps build a global vision for TB drug development.
The Host Targeting and Immunotherapy Task Force seeks to help create a new vision for TB treatment regimens by leveraging host targets and the immune system to shorten TB therapy when combined with existing TB antibiotics.
Candidates focuses on candidate TB drugs in the global pipeline, and promotes research and collaboration that will result in the creation of affordable, high-quality candidate drugs for the treatment of TB.
Critical Knowledge and tools promotes the understanding and development of tools needed for TB that will support the discovery, testing, or improvement of new TB drugs or treatment strategies that will ultimately be combined into novel TB regimens for clinical trials.
Clinical Trials Capacity supports successful clinical development with several initiatives, including the building of trials site capacity and identification of regulatory issues and hurdles.